RELPI
4.1.2022 15:02:06 CET | Business Wire | Press release
The Real Estate Limited Partner Institute (RELPI) today announced the expansion of its compelling Interests Aligned programs to Europe and the United Kingdom with the appointment of institutional real estate investment and media professional Arno Van Grondelle as CEO of RELPI Europe.
RELPI’s intimate, focused and curated local meet-ups foster open conversation and deep relationships among leading stakeholders in the investment and allocation of capital in real estate. The series was formally launched in 2021 with events in Austin, New York and Philadelphia, and was met with an overwhelming interest and attendance. In addition to the expansion into Europe and the United Kingdom, RELPI has announced events in Chicago, Cleveland, Los Angeles, San Francisco and New York so far in 2022.
“Our success and expansion reflect the pent-up demand for in-person gatherings and virtual meetings of informed, high-level executives to share insights, ideas and transparent conversations devoted to best practices in institutional real estate asset allocation and investment,” said RELPI’s CEO and Executive Director Jonathan Schein. “In less than six months, the RELPI community has grown to include more than 125 pension funds, endowments foundations and family offices, as well as more than 50 fund managers.”
The addition of Arno Van Grondelle as CEO of RELPI Europe will accelerate this expansion. Mr. Van Grondelle brings extensive knowledge and leadership experience from his many years working in the institutional real estate investment and media industries. Most recently he served as Managing Director of Europe at Institutional Real Estate Inc., responsible for client relations, business development and sales for Institutional Real Estate Europe magazine. He previously served as International Sales Director at PropertyEU, where he was responsible for the sales of PropertyEU's comprehensive media portfolio, including PropertyEU magazine and EXPO Real's Preview and Daily News.
"Arno’s wealth of knowledge, experience and relationships in the European investor and LP arena will solidify RELPI’s fast mover status in the industry,” said Mr. Schein "His professionalism and market acumen will make a great addition to our growing platform designed to connect key players for the mutual benefit of the dynamic private equity real estate investment and capital industries.”
“I am very excited to join RELPI and further build this community in Europe,” said Mr. Van Grondelle. “We are dedicated to bringing together real estate institutional investors, fund managers, operating companies and those organizations allied to the industry on a local, regional and global scale.”
The Interests Aligned series are designed to be streamlined and efficient (just three hours long) with a strong emphasis on social networking, offering RELPI’s unique value proposition – intimate, ultrahigh-value gatherings, in a streamlined, economically effective manner, with “proximity” in mind.
For more information about the Interests Aligned series, to register or inquire about membership, please visit: www.RELPI.org
About RELPI
As an established producer of successful meetings, events and conferences devoted to the global institutional investment community for the commercial real estate class, with “proximity” as the prime value proposition, RELPI is perfectly positioned to deliver a best-of-both-worlds solution: intimate, ultrahigh-value gatherings in a streamlined, economically effective way. From “virtual salons” and global summits focused on investors in all major global markets, to emerging manager programs and even “private label,” bespoke roundtables, RELPI is enabling tomorrow’s business connectivity today.
https://www.relpi.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005129/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom